Generation Bio (NASDAQ:GBIO) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Generation Bio (NASDAQ:GBIO) in a report released on Thursday morning,RTT News reports. They currently have a $5.00 target price on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Generation Bio in a research report on Wednesday, October 23rd.

Generation Bio Price Performance

Shares of NASDAQ GBIO traded down $0.12 during midday trading on Thursday, hitting $2.26. The stock had a trading volume of 185,842 shares, compared to its average volume of 181,326. The company’s 50-day simple moving average is $2.41 and its 200 day simple moving average is $2.74. The firm has a market cap of $150.83 million, a P/E ratio of -1.00 and a beta of 2.82. Generation Bio has a fifty-two week low of $1.02 and a fifty-two week high of $4.65.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The company had revenue of $4.09 million during the quarter, compared to the consensus estimate of $3.23 million. Generation Bio had a negative net margin of 1,202.56% and a negative return on equity of 92.86%. Equities analysts expect that Generation Bio will post -1.8 EPS for the current fiscal year.

Institutional Trading of Generation Bio

A number of large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Generation Bio during the first quarter worth $74,000. PFG Advisors bought a new stake in shares of Generation Bio in the first quarter valued at about $41,000. Vanguard Group Inc. boosted its position in shares of Generation Bio by 0.7% during the first quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock worth $10,462,000 after buying an additional 18,205 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Generation Bio by 113.9% during the first quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock worth $1,952,000 after buying an additional 255,468 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Generation Bio by 28.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock valued at $36,136,000 after buying an additional 1,952,187 shares during the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.